Chronic kidney disease (CKD) is associated with a wide number of abnormalities in mineral metabolism. Often, these alterations are the leading players in the development of comorbidities associated with CKD, which are risk factors of mortality. In this context, mineral and bone disorder associated with CKD (CKD-MBD) are highlighted, connecting bone, renal, and cardiovascular disorders. Many studies have been led to propose strategies to avoid, reduce, or slow down CKD-MBD progression using different compositions of metallic elements-based P binders such as aluminum, magnesium, or calcium. Magnesium, the aim of this review, has been used by nephrologists to treat CKD-MBD with a variable acceptation due mainly to different results on bone homeostasis. Nowadays, we have new evidence about the efficacy of magnesium supplementation on vascular calcification, renal function, and bone disorders, suggesting potential beneficial effects of Magnesium in the management of CKD-MBD.

中文翻译：

---

镁：在CKD-MBD背景下重访的一位老玩家。

慢性肾脏疾病（CKD）与多种矿物质代谢异常有关。通常，这些改变是与CKD相关的合并症发展的主要参与者，而CKD是导致死亡的危险因素。在这种情况下，与CKD相关的矿物质和骨骼疾病（CKD-MBD）突出显示，连接了骨骼，肾脏和心血管疾病。导致许多研究提出了使用不同成分的基于金属元素的P粘合剂（例如铝，镁或钙）来避免，减少或减缓CKD-MBD进展的策略。镁是本研究的目的，主要由于骨稳态的不同结果，肾脏病学家已将镁用于治疗CKD-MBD的接受程度可变。如今，